# Volatilomic response to targeted cancer therapy in vitro

**Authors:** Philip K. H. Leung, Innah Kim, Bibek Das, George B. Hanna

PMC · DOI: 10.1038/s41598-025-04886-5 · Scientific Reports · 2025-06-03

## TL;DR

This study explores how volatile organic compounds (VOCs) in cancer cells can indicate treatment response, potentially aiding precision medicine.

## Contribution

The study identifies a novel link between lipid-derived VOCs and drug resistance in colorectal cancer cells.

## Key findings

- mTORci-resistant cancer cells show distinct VOC signatures like alkenes, aldehydes, and fatty acids.
- These VOCs correlate with phospholipid structure and desaturation positions.
- The findings suggest VOCs could serve as biomarkers for treatment response.

## Abstract

Clinical advancement of novel therapeutics is often hindered by variable patient responses. Therefore, clinically translatable biomarkers of response are urgently required to facilitate precision medicine trials. Endogenous volatile organic compounds (VOCs) can be non-invasively detected in exhaled breath and biofluids and have shown great potential for early cancer detection. Since emerging evidence suggests that cancer-associated VOCs may reflect alterations in the tumour lipidome, we speculated that the response to metabolically active therapies could be monitored through VOC measurement. In this proof-of-concept study, we investigated the lipidomic and volatilomic profiles of mTOR catalytic inhibitors (mTORci)-resistant and -sensitive colorectal cancer cells. Distinct lipid-derived VOC signatures, including upregulated alkenes, aldehydes, and fatty acids were observed in mTORci-resistant cells. These enriched VOCs correlated with phospholipid structure and desaturation positions, suggesting that they may be surrogates of dysregulated lipid metabolism. This novel association between VOCs and drug response establishes a precedent for further investigation into VOC biomarkers of treatment response. VOCs associated with therapy response in vitro need to be targeted in clinical trials to identify biomarkers that could be translated to monitor therapeutic response in a clinical setting.

The online version contains supplementary material available at 10.1038/s41598-025-04886-5.

## Linked entities

- **Chemicals:** alkenes (PubChem CID 32932), aldehydes (PubChem CID 6449839), fatty acids (PubChem CID 264)
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Diseases:** colorectal cancer (MESH:D015179), cancer (MESH:D009369)
- **Chemicals:** phospholipid (MESH:D010743), aldehydes (MESH:D000447), alkenes (MESH:D000475), fatty acids (MESH:D005227), VOC (MESH:D055549), lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12134227/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12134227/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12134227/full.md

---
Source: https://tomesphere.com/paper/PMC12134227